DDInter1956 DDInter1492
A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Zalcitabine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Ponatinib
Zalcitabine {u} (Compound) upregulates {v} (Gene) TRAPPC6A
TRAPPC6A {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Zalcitabine {u} (Compound) downregulates {v} (Gene) CANT1
CANT1 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Zalcitabine {u} (Compound) causes {v} (Side Effect) Migraine
Migraine {u} (Side Effect) is caused by {v} (Compound) Ponatinib
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Zalcitabine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Zalcitabine {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is regulated by {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Zalcitabine {u} (Compound) upregulates {v} (Gene) TRAPPC6A
TRAPPC6A {u} (Gene) is regulated by {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ponatinib
Zalcitabine {u} (Compound) downregulates {v} (Gene) CANT1
CANT1 {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Zalcitabine {u} (Compound) causes {v} (Side Effect) Migraine
Migraine {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Zalcitabine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Zalcitabine (Compound) upregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is upregulated by Ponatinib (Compound)
Zalcitabine (Compound) downregulates CANT1 (Gene) and CANT1 (Gene) is downregulated by Ponatinib (Compound)
Zalcitabine (Compound) causes Migraine (Side Effect) and Migraine (Side Effect) is caused by Ponatinib (Compound)
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Zalcitabine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Zalcitabine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is regulated by IKBKB (Gene) and IKBKB (Gene) is upregulated by Ponatinib (Compound)
Zalcitabine (Compound) upregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is regulated by ABCB1 (Gene) and ABCB1 (Gene) is bound by Ponatinib (Compound)
Zalcitabine (Compound) downregulates CANT1 (Gene) and CANT1 (Gene) is downregulated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Zalcitabine (Compound) causes Migraine (Side Effect) and Migraine (Side Effect) is caused by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib